Enzo Biochem is a microcap company with a $30 million revenue run-rate Life Sciences business and $78-$85 million in cash. The company is likely being prepared for sale, with interest from potential ...

FARMINGDALE, NY, March 16, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) announced today that it has entered into an agreement for Labcorp (NYSE: LH) to acquire the assets of Enzo's Clinical ...

FARMINGDALE, NY, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company") today announced financial results for the fourth quarter ended July 31, 2023, and the fiscal ...

Enzo Biochem shareholders frustrated with lack of capital returns following Clinical Labs sale to Labcorp Holdings. Stock trading near historic lows, but potential for attractive returns with ...

Enzo Life Sciences is proud to introduce the SCREEN-WELL® Stem Cell Library, a collection of 130 readyto-use compounds for diverse stem cell research. It contains small molecules that can be used to ...

FARMINGDALE, NY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of ...

Enzo Life Sciences, Inc. is a wholly owned subsidiary of Enzo Biochem, Inc. headquartered in Farmingdale, New York. The company is organized to lead in the development, production, marketing, and ...

Enzo Life Sciences Develops, Produces, and Markets a Range of Life Sciences Research Reagents Enzo Life Sciences manufactures and markets biomedical research products and tools, which are critical not ...

Enzo Biochem, Inc. announced that it has been notified by the New York Stock Exchange (NYSE) of its non-compliance with listing standards due to its market capitalization and stockholder equity ...